



**A life saving cell and  
gene therapy company**

Annual General Meeting  
27 May 2022



# Welcome

---

## Roch Doliveux, Chair of the Board

- Saving patients' lives through innovative cell and gene therapies
- Continued large scale-manufacture of the Oxford AstraZeneca vaccine during 2021
- Expanded our partnership with Boehringer Ingelheim and signed agreements with Immatics, Arcellx and in post period Cabaletta Bio
- Established Oxford Biomedica Solutions in Boston, US in March 2022
- Delighted to welcome Dr Michael Hayden, Catherine Moukheibir and Dr. Namrata P. Patel to their first AGM and the Board



- John Dawson retires from the Board and we thank John for his many years of service



**A life saving cell and  
gene therapy company**

Annual General Meeting  
27 May 2022

Proxy Voting Results



## AGM 2022 proxy voting results

Resolution	In favour <small>(incl votes at Chairman and his discretion)</small>		Against		Withheld
1	62,334,596	99.99%	3,804	0.01%	907,786
2	48,610,227	77.89%	13,801,220	22.11%	834,739
3	53,341,068	85.16%	9,295,954	14.84%	609,164
4	62,549,843	99.86%	86,921	0.14%	609,422
5	62,547,861	99.86%	88,903	0.14%	609,422
6	59,589,629	96.34%	2,264,491	3.66%	1,392,066
7	60,060,802	95.89%	2,575,962	4.11%	609,422
8	62,520,953	99.81%	116,069	0.19%	609,164
9	62,007,361	98.99%	629,661	1.01%	609,164

## AGM 2022 proxy voting results

Resolution	In favour <small>(incl votes at Chairman and his discretion)</small>		Against		Withheld
10	57,804,835	92.29%	4,832,187	7.71%	609,164
11	55,510,324	88.62%	7,126,698	11.38%	609,164
12	62,327,459	99.51%	309,305	0.49%	609,422
13	62,633,239	99.99%	7,494	0.01%	605,453
14	62,634,198	99.99%	6,921	0.01%	605,067
15	58,157,231	92.86%	4,471,767	7.14%	617,188
16	61,689,659	98.50%	937,061	1.50%	619,466
17	61,724,145	98.56%	903,407	1.44%	618,634
18	60,151,778	96.03%	2,489,321	3.97%	605,087

# Conclusion of formal business

---

## **Roch Doliveux, Chair of the Board**

- This concludes the formal business of the Meeting
- Stuart Paynter our CFO will deliver an update on the Company's progress during the last twelve months
- Voting will remain open throughout the presentation and the following Q&A session that follows



A life saving cell and  
gene therapy company

May 2022



# Forward Looking Statements

---

This presentation does not constitute an offer to sell or a solicitation of offers to buy Ordinary Shares (the “Securities”). Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, the contents of this presentation have not been formally verified by Oxford Biomedica plc (the “Company”) or any other person. Accordingly, no representation or warranty, expressed or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this presentation, and no reliance should be placed on such information or opinions. Further, the information in this presentation is not complete and may be changed. Neither the Company nor any of its respective members, directors, officers or employees nor any other person accepts any liability whatsoever for any loss howsoever arising from any use of such information or opinions or otherwise arising in connection with this presentation.

This presentation may contain forward-looking statements that reflect the Company's current expectations regarding future events, its liquidity and results of operations and its future working capital requirements. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the success of the Company's development strategies, the successful and timely completion of clinical studies, securing satisfactory licensing agreements for products, the ability of the Company to obtain additional financing for its operations and the market conditions affecting the availability and terms of such financing.



# Science based innovative services company with a proprietary pipeline

1

## A leader in viral vectors within the fast-growing cell and gene therapy industry

First FDA approved lentiviral vector-based gene delivery system through our collaboration with Novartis on Kymriah®

Multiple partnerships with leading companies



2

## Diversified business with process development and manufacturing revenues with long term upside from our proprietary pipeline

Process development and manufacturing operations with regulatory approved facilities provide multiple revenue streams

Leveraging expertise to deliver innovative therapies through our proprietary pipeline

3

## Established operational infrastructure and proven commercial supply capabilities

Proven commercial supply capability in 30 countries

Over 810 staff located at 6 UK-based facilities covering in excess of 200,000 sqft<sup>1</sup>


As of March 2022, c.125 employees based in Boston, US



1. Includes manufacturing, laboratory and office space

# A leading viral vector specialist using science to save lives

## Delivering on Our Strategy to Become a Global Viral Vector Leader



Proprietary platform



IP: patents and know-how



Quality Systems



Expertise



Facilities

### Process development and manufacturing provides multiple revenue streams

Commercial Stage Viral Vector Innovative Service Provider  
with >25 years Experience  
UK (Oxford) and US (Boston) manufacturing facilities

**19** Partner Programmes

### Gene Therapeutics


Delivering innovative therapies

**5** Proprietary Products



# Viral Vector Manufacturing to Continue its Growth Trajectory

**Global Viral Vector Supply (Outsourced)<sup>1</sup>**  
(In \$ billions)




**Entire market now fully addressable with multi-site, multi-technology capable labs & manufacturing**

1. Source: Company estimates and third party research

# Oxford Biomedica AAV Manufacturing and Innovation Business: A High Performing Process Development and Manufacturing Platform

- In January 2022, Oxford Biomedica announced it was broadening its leading viral vector offerings by incorporating Homology Medicines' established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the US with Homology Medicines as 20% owner<sup>1</sup>



**Location**  
Boston, Massachusetts,  
United States

**Employees**  
Team of c.125 with  
AAV manufacturing  
expertise


**Manufacturing  
Capabilities**  
Process / Analytical  
Development & early stage  
clinical manufacturing at 500L,  
proven scalability to 2,000L for  
commercial supply

**25,000 sq.ft  
Manufacturing  
Capacity & Facility**  
State-of-the-art GMP facility  
10 – 15 500L batches  
10 – 15 1,000L batches  
annually at steady state<sup>2</sup>

**Platform & IP**  
Proprietary 'plug and play'  
manufacturing process and  
platform

**c.\$25m (£19m)  
Contracted Revenues**  
Minimum contracted revenues  
in the first full twelve  
months of operation

**Profitability**  
Break-even expected by  
year 3 with gold standard  
long term target margins



1. The transaction completed on 11<sup>th</sup> March 2022

2. Company estimates

GBP:USD = 1.33726

# Innovative CDMO Services

## Customer-centric

Leading provider of  
scale up solutions and  
commercial supply



# Innovative Services: 2021-22 Highlights

## COVID-19 Vaccine and Agreement with AstraZeneca

- Large-scale commercial manufacture of COVID-19 vaccine at Oxbox, running three suites at 1000L scale; discussions continue on a potential extension of the 18-month supply agreement with AstraZeneca

## Novartis

- **Dec 2021:** Novartis and OXB extended and updated their commercial supply agreement; OXB regained rights to three CAR-T targets (inc. CD19 targeted therapies) and Novartis has additional flexibility and no minimum order commitment

## Boehringer Ingelheim

- **Apr 2021:** Entered into a new three-year development and supply agreement with Boehringer Ingelheim for the manufacture and supply of various types of viral vectors
- **Oct 2021:** Boehringer Ingelheim exercised its option to license Oxford Biomedica's lentiviral vector technology to manufacture, register and commercialise BI 3720931

## New partnerships

- **Nov 2021:** Signed a new agreement with Immatics, a leading company developing T-cell-redirecting cancer immunotherapies
- **Dec 2021:** Announced a new license and supply agreement and a three-year clinical supply agreement with Arcellx, and is currently working on their lead CAR-T programme
- **Jan 2022:** Announced a Licence and Supply Agreement with Cabaletta Bio for their DSG3-CAART programme

## Building the Future

- Conversion of office space into GMP grade laboratories at Windrush Court completed
- First fill / finish suite at Oxbox has been qualified and regulatory submission to the MHRA has been made
- **Sep 2021:** Serum Life Sciences Ltd invested £50 million which will fund the development of the fallow area at Oxbox

## Expansion into US and AAV

- **Mar 2022:** OXB acquired Homology Medicines' established AAV capabilities to form a new AAV Manufacturing and Innovation Business in the US

**Platform**


**Innovation-centric  
Driving  
industrialisation of  
viral vectors**



# Proprietary Platform Innovation

**Maximising data integration and analysis**


**AI and machine learning**



**Targeted vectors with optimal/regulated expression**

**Cell and vector engineering to increase capability and productivity**

**Automation for increased productivity**




**Therapeutic vectors with tailored attributes**


**Proteomics/transcriptomics**





**Analytical dev. to characterise vectors (purity) and achieve rapid batch release**



**LentiStable™**



**Process D: Producer cell lines**



**Process C: Higher titre and superior quality – Includes Perfusion, U1 (RNA) & U2**



**Large scale bioprocessing: Increase yield and improve purity**







# Gene Therapeutics

**Patient-centric**  
Leveraging  
expertise to deliver  
lentiviral vector  
based gene  
therapies

# Gene therapeutics update

---

## Appointment of new Chief Medical Officer

- Dr. Rao joined OXB in April 2022, with responsibility for developing the OXB therapeutic product strategy – both by building on our existing product pipeline and further evaluating novel areas of opportunity

## Proprietary in-house product development

- Select set of products being developed for which external funding will be sought
- Lead programme: OXB-302 – Acute Myeloid Leukaemia, CAR-T therapy for AML targeting 5T4 – preparation for clinical trial initiation ongoing
- Liver gene therapy – liver is an attractive target for Lentiviral vectors due to potential one-off therapy to give life-long benefit
- *In vivo* CAR T generation for greater patient access and superior efficacy. Off the shelf, reduced COGs direct reprogramming of patient's cells

## AXO-Lenti-PD – Parkinson's Disease

- On 31st January 2022, Oxford Biomedica was informed by Sio Gene Therapies of their intention to return the rights for AXO-Lenti-PD. We plan to out-license the programme again to a suitable partner

# Summary and Outlook



## 2021 was an exceptional year of performance for Oxford Biomedica

---

- 1 Revenues grew by 63% to £143 million with operating EBITDA of £36 million (exceptional performance driven by large scale commercial manufacture of AstraZeneca's COVID-19 vaccine)**
- 2 Signed 2 new partners, expanded on existing longstanding partnerships**
- 3 Expanded scope to broaden offering to all key viral vector types**
- 4 Strengthened board with three new board appointments – bringing additional scientific and translational expertise**

## Outlook for 2022

---





## Contact Us

---

**Oxford Biomedica plc**  
Windrush Court  
Transport Way  
Oxford  
OX4 6LT

**Stuart Paynter** Chief Financial Officer  
**Sophia Bolhassan** Head of IR

+44 (0) 1865 783 000  
[IR@oxb.com](mailto:IR@oxb.com)  
[www.oxb.com](http://www.oxb.com)

# Shareholder Q&A

## Roch Doliveux, Chair of the Board

- Shareholder Q&A session of the meeting is now open
- If you have yet to cast your vote please continue to do so as the poll will close at the end of the Q&A session



- 1 A leader in viral vectors within the fast growing cell and gene therapy industry
- 2 Diversified business with process development and manufacturing revenues with long term upside from our proprietary pipeline
- 3 Established operational infrastructure and proven commercial supply capabilities

## Poll is now closed

---

### **Roch Doliveux, Chair of the Board**

- Poll is now closed
- The final poll results will be available on our website in due course
- This concludes the Meeting and thank you for attending